Niagen Bioscience (STU:OCD1) Cyclically Adjusted Book per Share: €0.54 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:OCD1 Niagen Bioscience Inc STU:OCD1
69 GF Score
Price €2.60
GF Value €4.19
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Niagen Bioscience Cyclically Adjusted Book per Share?

Niagen Bioscience STU:OCD1 -2.26% 69 Cyclically Adjusted Book per Share is €0.54 as of Jun. 2026. GuruFocus rates STU:OCD1 with a GF Score™ of 69/100 and a GF Value™ of €4.19 (Possible Value Trap). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Niagen Bioscience's adjusted book value per share for the three months ended in Jun. 2026 was €0.868. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.54 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Niagen Bioscience's average Cyclically Adjusted Book Growth Rate was 17.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 11.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 11.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Niagen Bioscience was 19.90% per year. The lowest was 8.80% per year. And the median was 10.10% per year.

As of today (2026-08-11), Niagen Bioscience's current stock price is €2.60. Niagen Bioscience's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €0.54. Niagen Bioscience's Cyclically Adjusted PB Ratio of today is 4.81.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Niagen Bioscience was 43.53. The lowest was 2.93. And the median was 13.03.


Niagen Bioscience  (STU:OCD1) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Niagen Bioscience's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.60/0.54
=4.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Niagen Bioscience was 43.53. The lowest was 2.93. And the median was 13.03.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Niagen Bioscience Cyclically Adjusted Book per Share Related Terms


Niagen Bioscience Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Niagen Bioscience's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Niagen Bioscience Cyclically Adjusted Book per Share Chart

Niagen Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.33 0.37 0.41 0.48 0.49

Niagen Bioscience Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 0.49 0.49 0.51 0.54

STU:OCD1 vs LCTX, IFRX, VRXA: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Niagen Bioscience's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Niagen Bioscience Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Niagen Bioscience's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Niagen Bioscience's Cyclically Adjusted PB Ratio falls into.


STU:OCD1
69GF Score
Niagen Bioscience Inc STU:OCD1
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Niagen Bioscience Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Niagen Bioscience's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.868/333.9520*333.9520
=0.868

Current CPI (Jun. 2026) = 333.9520.

Niagen Bioscience Quarterly Data

Book Value per Share CPI Adj_Book
201609 0.281 241.428 0.389
201612 0.252 241.432 0.349
201703 0.231 243.801 0.316
201706 0.502 244.955 0.684
201709 0.594 246.819 0.804
201712 0.832 246.524 1.127
201803 0.692 249.554 0.926
201806 0.632 251.989 0.838
201809 0.521 252.439 0.689
201812 0.434 251.233 0.577
201903 0.336 254.202 0.441
201906 0.242 256.143 0.316
201909 0.415 256.759 0.540
201912 0.309 256.974 0.402
202003 0.250 258.115 0.323
202006 0.312 257.797 0.404
202009 0.269 260.280 0.345
202012 0.218 260.474 0.279
202103 0.544 264.877 0.686
202106 0.514 271.696 0.632
202109 0.443 274.310 0.539
202112 0.412 278.802 0.493
202203 0.345 287.504 0.401
202206 0.288 296.311 0.325
202209 0.311 296.808 0.350
202212 0.363 296.797 0.408
202303 0.350 301.836 0.387
202306 0.335 305.109 0.367
202309 0.342 307.789 0.371
202312 0.348 306.746 0.379
202403 0.354 312.332 0.379
202406 0.378 314.175 0.402
202409 0.407 315.301 0.431
202412 0.569 315.605 0.602
202503 0.653 319.799 0.682
202506 0.699 322.561 0.724
202509 0.756 324.800 0.777
202512 0.820 324.054 0.845
202603 0.896 330.213 0.906
202606 0.868 333.952 0.868

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €0.54 mean?
Niagen Bioscience (STU:OCD1) has a Cyclically Adjusted Book per Share of €0.54 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Niagen Bioscience and its competitors.
Is Niagen Bioscience's Cyclically Adjusted Book per Share too high?
Niagen Bioscience's current Cyclically Adjusted Book per Share is €0.54. Overall, Niagen Bioscience has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Niagen Bioscience's Cyclically Adjusted Book per Share compare to LCTX and IFRX?
Niagen Bioscience's Cyclically Adjusted Book per Share of €0.54 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Niagen Bioscience and its competitors. Niagen Bioscience's current Cyclically Adjusted Book per Share is €0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Niagen Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Niagen Bioscience (STU:OCD1) is currently considered Possible Value Trap. The stock's GF Value™ is €4.19, compared to a current price of €2.60 — trading 37.9% below its estimated fair value. The current Cyclically Adjusted Book per Share is €0.54. Niagen Bioscience's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Niagen Bioscience (STU:OCD1), the current Cyclically Adjusted Book per Share is €0.54 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Niagen Bioscience (STU:OCD1) Overvalued in 2026?

Based on GuruFocus' analysis, Niagen Bioscience stock appears to be undervalued. The current stock price of €2.60 is trading 37.9% below its estimated GF Value™ of €4.19. GuruFocus considers Niagen Bioscience to be Possible Value Trap.

Key valuation signals for STU:OCD1:

  • Cyclically Adjusted Book per Share: €0.54
  • GF Value™: €4.19 vs. price of €2.60 (37.9% below fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the STU:OCD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Niagen Bioscience Business Description

Other Exchanges NAGE:USA
Address 10900 Wilshire Boulevard, Suite 600, Los Angeles, CA, USA, 90024
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
69GF Score

Get the complete analysis for STU:OCD1

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.60
Price
€4.19
GF Value